Mangoceuticals, Inc. Stock Price, News & Analysis

MangoRx, a developer of men's health products, announced that its Australian patent application for a new preventive care technology has been accepted. This follows a similar acceptance in Japan. The technology targets respiratory and orally transmitted infections using a formulation with GALALCOOL®️, zinc protoporphyrin IX, and tannins. This patent strengthens their global intellectual property portfolio, especially following MangoRx's recent acquisition of Intramont Technologies' patents. The official patent publication is set for June 6, 2024, with an anticipated deed issuance by September 6, 2024, barring any opposition. This move aligns with MangoRx’s mission to offer advanced health solutions worldwide.

MangoRx, a company specializing in men's health and wellness, has received a Notice of Allowance for its Japanese Patent Application No. 2021-545824. This patent, initially applied for by Intramont Technologies, covers a formulation designed to prevent oral and respiratory infections. The technology includes ingredients like GALALCOOL®️, zinc protoporphyrin IX, and tannins. This follows MangoRx's acquisition of Intramont's global patent portfolio, including U.S. Patent 11,517,523. The patent solidifies MangoRx's intellectual property and paves the way for introducing its products in Japan, aligning with its mission to offer advanced preventive care solutions.

MangoRx has announced the upcoming release of MOJO, a new oral dissolvable tablet aimed at treating low testosterone and male hormone imbalances. The product will combine Enclomiphene Citrate, Pregnenolone, and DHEA, and will be marketed to younger males as a $199 monthly subscription. MOJO is designed to stimulate natural testosterone production and support overall hormonal balance, offering a complementary alternative to MangoRx's existing PRIME Testosterone Replacement Therapy. The launch is scheduled before the end of Q2 2024, with the company aiming to capture a significant share of the growing testosterone replacement therapy market, projected to reach $2.9 billion by 2032.

Mangoceuticals announced the completion of its first batch of Mango ED oral dissolvable tablets (ODTs) for the Mexican and Latin American markets. These tablets, containing Tadalafil, will undergo tests in the U.S. for quality assurance. The next phase includes producing three additional lots for bioequivalence and stability testing in Mexico to meet COFEPRIS standards. This effort is in collaboration with Emifarma. The ED market in Mexico is valued at $216 million annually, growing at 4% per year. MangoRx aims to expand into other LATAM countries post-COFEPRIS certification.

MangoRx, a company specializing in men’s health and wellness products, announced a partnership with Crakmedia, an international performance marketing company. Crakmedia will spearhead MangoRx's digital marketing initiatives, utilizing their extensive experience in performance marketing, web development, and traffic monetization. Digital ads on Crakmedia's network reach up to 1.5 billion views daily across 150 countries. This collaboration aims to boost MangoRx's sales and market presence significantly. MangoRx will benefit from Crakmedia's 15 years of expertise, AI-driven compliance systems, and industry accolades. This partnership is expected to enhance MangoRx's ability to attract new customers and expand its product portfolio.

MangoRx, a men's health and wellness company, has announced the development of oral formulations of Semaglutide and Tirzepatide, branded as 'Slim' and 'Trim.' These drugs, traditionally available as injectables, are designed to aid in weight management. Clinical trials have shown impressive weight loss results, with Semaglutide yielding a 15.2% weight loss and Tirzepatide 15.7% over one year. The GLP-1 receptor agonists' market is projected to reach $164 billion by 2032. MangoRx's oral versions are expected to capture a significant market share due to patient preference for oral medications. The products will be available on MangoRx's telemedicine platform by Q3 2024, priced at $299/month for 'Slim' and $399/month for 'Trim.'

MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.

Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.